November 2, 2009 - Hologic Inc. is featuring the MammoSite ML radiation therapy system at ASTRO 2009, and will present data showing treatment with MammoSite ML resulted in acceptable ipsilateral breast tumor recurrence and axillary recurrence rates that are comparable with standard whole breast radiation therapy.

Hologic's MammoSite therapy system, first cleared by the FDA in 2002, is the most widely utilized and accepted method of accelerated partial breast irradiation (APBI) in the United States. With its multi-lumen design, the new MammoSite ML device gives radiation oncologists the ability to shape the radiation dose for typical cases and treat patients who are otherwise not appropriate candidates for traditional brachytherapy.

“The five-year American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry results are also being presented at this meeting,” Harding noted. “The data from the study is expected to show once again that treatment with the MammoSite system resulted in acceptable ipsilateral breast tumor recurrence and axillary recurrence rates that are comparable with standard whole breast radiation therapy. We also expect the registry data to show excellent breast cancer-specific survival. ”

In October Hologic began a limited market launch of MammoSite ML to train physicians and scale up for national distribution. The Company expects a full commercial launch by year end.
By employing the MammoSite system, the radiation oncologist can deliver targeted radiation therapy directly to the area where cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days. Additionally, targeted therapy of the breast limits radiation exposure to normal, healthy tissue. This targeting helps minimize side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs.

David Harding, senior vice president of Hologic's interventional breast solutions business, stated, “MammoSite ML is designed to provide radiation oncologists a lot more flexibility. And, we believe the parallel lumen design offers increased patient comfort and enables efficient treatment planning. With MammoSite ML, radiation oncologists should be able to easily satisfy the current clinical recommendation that the dose to the skin and ribs be maintained to less than 125 percent of the prescription dose.”

“ASTRO is the perfect venue to feature MammoSite ML,” Mr. Harding added. “The radiation oncology community will see firsthand our commitment to expanding the adoption of accelerated partial breast irradiation.”

For more information: www.hologic.com and www.mammosite.com


Related Content

News | Ultrasound Imaging

July 14, 2025 — Patients with liver diseases will have expanded access to advanced ultrasound imaging and transplant ...

Time July 14, 2025
arrow
News | Lung Imaging

June 9, 2025 — bioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive, accurate ...

Time July 10, 2025
arrow
News | Breast Imaging

July 8, 2025 — QT Imaging Holdings, has appointed Elaine Iuanow, MD, as chief medical officer (CMO) and Kim Du as senior ...

Time July 09, 2025
arrow
News | Breast Imaging

July 7, 2025 — SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, has ...

Time July 08, 2025
arrow
News | Image Guided Radiation Therapy (IGRT)

June 25, 2025 — Royal Philips and Indiana-based Methodist Hospitals recently announced the healthcare provider’s ...

Time June 25, 2025
arrow
News | Breast Imaging

June 25, 2025 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time June 25, 2025
arrow
News | Radiation Therapy

May 14, 2025 — Siemens Healthineers is investing $150 million in new projects to expand production, create jobs and ...

Time May 15, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
Subscribe Now